Molina Healthcare, Inc. revised earnings guidance for the year 2021. For the year, the company on a normalized basis, excluding the impacts of COVID, excluding any impacts from onetime items, they have comfortably exceeded their full year guidance, which, again, was developed on that same basis. Obviously, their $11.20 to $11.70 a share was developed long before COVID was a phenomenon and certainly didn't anticipate any windfall legal settlements. So $12 of normalized performance projected to exceed their full year GAAP guidance of $11.20 to $11.70 a share, which means they have a good jumping off point, a very solid baseline off of which to project 2021. The last time they updated on their premium revenue outlook for 2021, they said that was approximately $21.5 billion, which would be a 20% growth rate over 2020. They have now updated that, refined their estimate to $23 billion of premium revenue, a 25% increase over 2020. So now that the Magellan acquisition is done, they closed on it on New Year's eve. They will own it for the full year. $2.8 billion goes into the portfolio.